Cargando…

P1506: REAL-WORLD DATA ON THE USE OF LUSPATERCEPT IN GREEK PATIENTS WITH TRANSFUSION DEPENDENT THALASSEMIA

Detalles Bibliográficos
Autores principales:	Delaporta, P., Delicou, S., Kouraklis-Symeonidis, A., Diamantidis, M., Vlachaki, E., Xydaki, A., Labropoulou, V., Lazaris, V., Michalitsis, M., Klonizakis, P., Toutoudaki, K., Chatzieleftheriou, M.-I., Kyriakopoulou, D., Kattamis, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429186/ http://dx.doi.org/10.1097/01.HS9.0000848880.20537.13

Ejemplares similares

P1508: LUSPATERCEPT REDUCES THE BURDEN OF RED BLOOD CELL TRANSFUSION IN PATIENTS WITH BETA -THALASSEMIA AND COMORBIDITIES: THE EXPERIENCE OF A SINGLE THALASSEMIA AND SICKLE CELL UNIT IN A UNIVERSITY HOSPITAL
por: Delicou, S., et al.
Publicado: (2022)

Choroidal Thickness Evaluation in a Transfusion-Dependent Beta-Thalassemia Greek Population
por: Tsapardoni, Foteini, et al.
Publicado: (2020)

S124: ADVERSE EVENTS FOLLOWING COVID-19 VACCINATION IN TRANSFUSION-DEPENDENT -THALASSEMIA PATIENTS
por: Delaporta, P, et al.
Publicado: (2022)

PB2532: VARIABLE HEMATOLOGICAL AND CLINICAL PHENOTYPES IN DOUBLE HETEROZYGOTES OF ΒETA-THALASSEMIA AND TRIPLICATED ΑLPHA-GLOBIN GENES
por: Delaporta, Polyxeni, et al.
Publicado: (2023)

5610224 THE USE OF LUSPATERCEPT IN PATIENTS WITH β -THALASSAEMIA AND MULTIPLE SYSTEMIC COMPLICATIONS INCREASES HEMOGLOBIN LEVEL, DECREASES TRANSFUSION BURDEN, AND IS UNAFFECTED BY COMPLICATIONS. SINGLE THALASSEMIA AND SICKLE CELL DEPARTEMENT’S EXPERIENCE.
por: Manganas, K.M., et al.
Publicado: (2023)

Luspatercept for transfusion-dependent β-thalassemia: time to get real
por: Musallam, Khaled M., et al.
Publicado: (2023)

P1507: CLINICAL PROFILE OF COVID-19 INFECTION AND IMMUNE RESPONSE AFTER 3AND6 MONTH VACCINATION AGAINST SARS-COV-2 IN ADULT PATIENTS WITH TRANSFUSION-DEPENDENT THALASSAEMIA-THE EXPERIENCE OF A GREEK CENTER
por: Delaporta, P., et al.
Publicado: (2022)

P1518: LONG-TERM SAFETY RESULTS OF THE BELIEVE STUDY OF LUSPATERCEPT IN ADULTS WITH ΒETA-THALASSEMIA
por: Viprakasit, V., et al.
Publicado: (2022)

Capitulaciones colombinas (1492-1506) /
por: Fernández, Rafael Diego
Publicado: (1987)

P795: NEUTROPENIA IN CHILDHOOD IS MOST FREQUENTLY DUE TO AN AUTOIMMUNE PROCESS AND HAS A BENIGN COURSE.
por: Toutoudaki, Konstantina, et al.
Publicado: (2023)

Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy
por: Musallam, Khaled M, et al.
Publicado: (2023)

Efficacy and Safety of Luspatercept in the Treatment of β-Thalassemia: A Systematic Review
por: Dighriri, Ibrahim M, et al.
Publicado: (2022)

Pure Red Cell Aplasia and Lymphoproliferative Disorders: An Infrequent Association
por: Vlachaki, Efthymia, et al.
Publicado: (2012)

1506. Outcomes of Standardized Neonatal Cephalexin Dosing
por: Robertson, Melena J, et al.
Publicado: (2019)

Luspatercept‐induced reduction in transfusion requirement in α‐thalassemia
por: Jackson, Nicholas, et al.
Publicado: (2020)

Adverse Events Following COVID-19 Vaccination in Transfusion-Dependent -Thalassemia Patients
por: Delaporta, Polyxeni, et al.
Publicado: (2021)

P1466: EFFECT OF LUSPATERCEPT ON BONE MINERAL DENSITY IN PATIENTS WITH BETA‑THALASSEMIA ENROLLED IN THE PHASE 3 BELIEVE TRIAL
por: Coates, Thomas D., et al.
Publicado: (2023)

Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence
por: Longo, Filomena, et al.
Publicado: (2023)

Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia
por: Piga, Antonio, et al.
Publicado: (2022)

P130: PROVIDING ADEQUATE HEALTHCARE TO PEOPLE WITH HEMOGLOBINOPATHIES DURING THE PANDEMIC (COVID-19)
por: Sophia Delicou, S, et al.
Publicado: (2022)

Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes
por: Tinsley-Vance, Sara M., et al.
Publicado: (2023)

Twelve‐lead and signal‐averaged electrocardiographic parameters among beta‐thalassemia major patients
por: Patsourakos, Dimitrios, et al.
Publicado: (2020)

5613475 ADVERSE REACTIONS TO RBC TRANSFUSION: A SINGLE THALASSEMIA AND SICKLE CELL DISEASE DEPARTMENT’S EXPERIENCE
por: Xydaki, A.X., et al.
Publicado: (2023)

P1517: REAL-WORLD COMPLICATION BURDEN AND DISEASE MANAGEMENT IN TRANSFUSION-DEPENDENT ADULTS WITH ΒETA-THALASSEMIA (Β-THAL) IN GREECE: FINAL RESULTS OF THE EPIDEMIOLOGICAL CROSS-SECTIONAL ULYSSES STUDY
por: Kattamis, A., et al.
Publicado: (2022)

S273: LONG-TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON-TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL
por: Taher, Ali T., et al.
Publicado: (2023)

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022)

5610178 SURVIVAL AND COMPLICATIONS IN PATIENTS WITH HEMOGLOBINOPATHIES: THE EXPERIENCE OF A SINGLE DEPARTMENT OF THALASSEMIA AND SICKLE DISEASE
por: Xydaki, X.A., et al.
Publicado: (2023)

1506. Association of Antibiotic Treatment Duration with First Recurrence of Uncomplicated Urinary Tract Infection in Pediatric Patients
por: Afolabi, Titilola M, et al.
Publicado: (2018)

Population Pharmacokinetics and Exposure‐Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β‐Thalassemia
por: Chen, Nianhang, et al.
Publicado: (2020)

Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis
por: Hatzimichael, Eleftheria, et al.
Publicado: (2022)

PB2535: TRIAL IN PROGRESS: A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LUSPATERCEPT TO TREAT ANEMIA IN ADULTS WITH ALPHA-THALASSEMIA
por: Viprakasit, Vip, et al.
Publicado: (2023)

P798: DIAMOND BLACKFAN ANEMIA MAY ESCAPE DIAGNOSIS UP TO ADULTHOOD; A REPORT FROM THE UPDATED GREEK REGISTRY
por: Delaporta, Polyxeni, et al.
Publicado: (2023)

The GADD45A (1506T>C) Polymorphism Is Associated with Ovarian Cancer Susceptibility and Prognosis
por: Yuan, Cunzhong, et al.
Publicado: (2015)

1506. Prevalence of Histoplasma Antigenuria among an outpatient Advanced HIV cohort in Kampala,Uganda
por: Sekar, Preethiya, et al.
Publicado: (2023)

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes
por: Komrokji, Rami S., et al.
Publicado: (2023)

Impact of ZBTB7A hypomethylation and expression patterns on treatment response to hydroxyurea
por: Chondrou, Vasiliki, et al.
Publicado: (2018)

Immune Response of Adult Sickle Cell Disease Patients after COVID-19 Vaccination: The Experience of a Greek Center
por: Varelas, Christos, et al.
Publicado: (2022)

Serum Levels of S100b and NSE Proteins in Patients with Non-Transfusion-Dependent Thalassemia as Biomarkers of Brain Ischemia and Cerebral Vasculopathy
por: Kanavaki, Aikaterini, et al.
Publicado: (2017)

HTR for Greek Historical Handwritten Documents
por: Tsochatzidis, Lazaros, et al.
Publicado: (2021)

Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept
por: Delanghe, Sigurd, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7n142nm9vf4noppelldapvna45